Avoro Capital Advisors LLC holds a focused book of 30 stocks worth $10.2B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Cytokinetics Inc and trimmed Ascendis Pharma A/s. Their largest long position is United Therapeutics Corp at 15% of the equity book. They also disclosed $13.3M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1633313/holdings"
Use Arkolith to show Avoro Capital Advisors LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
80% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | United Therapeutics Corp Common | $1.6B | 2.63M | 15.4% | ▲+0.9% Added · +24K sh | |
| 2 | Ascendis Pharma Sponsored ADR | $1.2B | 5.06M | 11.4% | ▼−0.9% Reduced · −49K sh | |
| 3 | Madrigal Pharmaceuticals Inc Common | $951.8M | 1.82M | 9.4% | ▲+0.6% Added · +11K sh | |
| 4 | Krystal Biotech Inc Common | $746.3M | 2.89M | 7.4% | —Held | |
| 5 | Argenx SE Sponsored ADR | $730.3M | 1.00M | 7.2% | ▲+1.0% Added · +10K sh | |
| 6 | Arrowhead Pharmaceuticals Inc Common | $670.9M | 10.70M | 6.6% | ▲+0.7% Added · +75K sh | |
| 7 | Kymera Therapeutics Inc Common | $622.6M | 7.47M | 6.1% | —Held | |
| 8 | Apellis Pharmaceuticals Inc Common | $491.7M | 12.22M | 4.8% | —Held | |
| 9 | Centessa Pharmaceuticals PLC SPONSORED ADS | $454.0M | 11.43M | 4.5% | ▼−21% Reduced · −3.1M sh | |
| 10 | Celcuity Inc Common | $385.2M | 3.38M | 3.8% | ▲+8.5% Added · +264K sh | |
| 11 | Xenon Pharmaceuticals Inc Common | $336.0M | 5.78M | 3.3% | ▲+6.5% Added · +353K sh | |
| 12 | Structure Therapeutics Inc SPONSORED ADS | $316.0M | 6.56M | 3.1% | —Held | |
| 13 | Terns Pharmaceuticals Inc Common | $300.2M | 5.70M | 3.0% | ▲+31% Added · +1.3M sh | |
| 14 | Vera Therapeutics Inc Common | $236.9M | 5.89M | 2.3% | —Held | |
| 15 | Revolution Medicines Inc Common | $228.0M | 2.34M | 2.2% | ▲+8.0% Added · +174K sh | |
| 16 | Cytokinetics Inc Common | $219.7M | 3.33M | 2.2% | ▲New New position | |
| 17 | Ocular Therapeutix Inc Common | $104.3M | 12.31M | 1.0% | ▲+14% Added · +1.5M sh | |
| 18 | Damora Therapeutics Inc Common | $98.0M | 3.78M | 1.0% | ▲New New position | |
| 19 | Uniqure NV Common | $97.4M | 5.96M | 1.0% | ▼−3.1% Reduced · −190K sh | |
| 20 | Taysha Gene Therapies Inc Common | $97.0M | 21.70M | 1.0% | —Held | |
| 21 | Definium Therapeutics Inc Common | $94.5M | 5.00M | 0.9% | ▲New New position | |
| 22 | Soleno Therapeutics Inc Common | $77.0M | 2.30M | 0.8% | ▼−21% Reduced · −600K sh | |
| 23 | Alkermes PLC Common | $42.4M | 1.20M | 0.4% | ▼−14% Reduced · −200K sh | |
| 24 | Septerna Inc Common | $32.1M | 1.34M | 0.3% | —Held | |
| 25 | Viridian Therapeutics Inc Common | $29.3M | 1.50M | 0.3% | —Held | |
| 26 | GH Research PLC ORDINARY SHARES | $25.3M | 1.80M | 0.2% | —Held | |
| 27 | Avalo Therapeutics Common | $21.1M | 1.41M | 0.2% | ▲New New position | |
| 28 | Lexeo Therapeutics Inc Common | $10.8M | 1.88M | 0.1% | ▼−43% Reduced · −1.4M sh | |
| 29 | Whitehawk Therapeutics Inc Common | $9.8M | 2.85M | 0.1% | —Held | |
| 30 | Mannkind Corp Common | $5.4M | 2.20M | 0.1% | ▼−50% Reduced · −2.2M sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | UNITED THERAPEUTICS CORPUTHR | $10.3M | 380K |
| CALL · bullish | CELCUITY INCCELC | $3.0M | 200K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 33 | $10.2B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Mar 16, 2026 | 34 | $10.2B | 13F-HR/A |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 32 | $7.7B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 30 | $5.7B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 33 | $6.4B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 39 | $7.1B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 36 | $6.9B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 41 | $7.5B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 46 | $8.6B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 42 | $7.2B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 46 | $6.4B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 43 | $7.4B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 41 | $6.7B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 36 | $6.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 39 | $5.4B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 40 | $5.1B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 43 | $5.5B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 41 | $5.9B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 52 | $6.4B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 46 | $5.7B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 46 | $5.8B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 44 | $5.8B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 46 | $7.0B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.